1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Genexine, Inc. - Product Pipeline Review - 2015

Genexine, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 30 pages

Genexine, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Genexine, Inc. - Product Pipeline Review - 2015’, provides an overview of the Genexine, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genexine, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Genexine, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genexine, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Genexine, Inc.’s pipeline products

Reasons to buy

- Evaluate Genexine, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genexine, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genexine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genexine, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genexine, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genexine, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Genexine, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Genexine, Inc. Snapshot 5
Genexine, Inc. Overview 5
Key Information 5
Key Facts 5
Genexine, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Genexine, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Genexine, Inc. - Pipeline Products Glance 12
Genexine, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Genexine, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Genexine, Inc. - Drug Profiles 15
GX-188E 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
GXE-2 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
GXH-9 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
HB-110E 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
GX-051 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
GXG-3 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
GXG-6 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Genexine, Inc. - Pipeline Analysis 22
Genexine, Inc. - Pipeline Products by Target 22
Genexine, Inc. - Pipeline Products by Route of Administration 23
Genexine, Inc. - Pipeline Products by Molecule Type 24
Genexine, Inc. - Pipeline Products by Mechanism of Action 25
Genexine, Inc. - Recent Pipeline Updates 26
Genexine, Inc. - Dormant Projects 27
Genexine, Inc. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30

List of Tables
Genexine, Inc., Key Information 5
Genexine, Inc., Key Facts 5
Genexine, Inc. - Pipeline by Indication, 2015 7
Genexine, Inc. - Pipeline by Stage of Development, 2015 8
Genexine, Inc. - Monotherapy Products in Pipeline, 2015 9
Genexine, Inc. - Partnered Products in Pipeline, 2015 10
Genexine, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Genexine, Inc. - Phase II, 2015 12
Genexine, Inc. - Phase I, 2015 13
Genexine, Inc. - Preclinical, 2015 14
Genexine, Inc. - Pipeline by Target, 2015 22
Genexine, Inc. - Pipeline by Route of Administration, 2015 23
Genexine, Inc. - Pipeline by Molecule Type, 2015 24
Genexine, Inc. - Pipeline Products by Mechanism of Action, 2015 25
Genexine, Inc. - Recent Pipeline Updates, 2015 26
Genexine, Inc. - Dormant Developmental Projects,2015 27

List of Figures
Genexine, Inc. - Pipeline by Top 10 Indication, 2015 7
Genexine, Inc. - Pipeline by Stage of Development, 2015 8
Genexine, Inc. - Monotherapy Products in Pipeline, 2015 9
Genexine, Inc. - Partnered Products in Pipeline, 2015 10
Genexine, Inc. - Pipeline by Top 10 Target, 2015 22
Genexine, Inc. - Pipeline by Top 10 Route of Administration, 2015 23
Genexine, Inc. - Pipeline by Top 10 Molecule Type, 2015 24
Genexine, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.